Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.37 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.37 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425925 | 0.80 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL83093 | 0.74 | — | — | |
| SCHEMBL3545805 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL14649692 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL3265548 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1471940 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| Hydrochloric Acid SCHEMBL15575093 | 0.72 | — | — | |
| SCHEMBL24721803 | 0.71 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL8978150 | 0.71 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL11819433 | 0.71 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4194434-A1 | POLYURETHANE, METHOD FOR PRODUCING POLYURETHANE, ELECTROCONDUCTIVE PASTE COMPOSITION, ELECTROCONDUCTIVE WIRE, AND METHOD FOR PRODUCING ELECTROCONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-4001336-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220157484-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| CN-109983037-B | Photoinitiator | 科洛普拉斯特公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3545009-B1 | PHOTOINITATORS | COLOPLAST AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| EP-3545009-B1 | PHOTOINITATORS | COLOPLAST AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-09-08 | — | — | US | disclosed |
| US-10696626-B2 | Photoinitators | COLOPLAST A/S (DK) | 2020-06-30 | — | — | US | disclosed |
| US-10696626-B2 | Photoinitators | COLOPLAST A/S (DK) | 2020-06-30 | — | — | US | disclosed |
| US-10669286-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-06-02 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2010096320-A2 | CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1711505-B1 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| US-20090043097-A1 | Methods | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| EP-1711505-A2 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | AstraZeneca AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005056563-A2 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043097-A1 | Methods | CYP21A2, CYP17A1, HSD17B7 | KCNA4 1632/4885KCNA1 2056/4885KCNAB1 1686/4885 |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | KCNA4 1625/4885KCNA1 3319/4885KCNAB1 3371/4885 |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | KCNA4 3568/4885KCNA1 3208/4885KCNAB1 4510/4885 |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | KCNA4 640/4885KCNA1 384/4885KCNAB1 346/4885 |
| US-10669286-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | KCNA4 1785/4885KCNA1 1528/4885KCNAB1 724/4885 |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | KCNA4 1248/4885KCNA1 2806/4885KCNAB1 2804/4885 |
| US-10696626-B2 | Photoinitators | CRY1, QDPR, CRY2 | KCNA4 4527/4885KCNA1 4335/4885KCNAB1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.